The efficacy of ezetimibe add-on with combination peginterferon plus ribavirin therapy in patients with chronic hepatitis C

DOI Web Site Web Site 35 References

Bibliographic Information

Other Title
  • Ｅｚｅｔｉｍｉｂｅ併用によるＣ型慢性肝疾患に対するＰｅｇｉｎｔｅｒｆｅｒｏｎ／Ｒｉｂａｖｉｒｉｎ療法の成績向上について
  • Ezetimibe ヘイヨウ ニ ヨル Cガタ マンセイ カン シッカン ニ タイスル Peginterferon Ribavirin リョウホウ ノ セイセキ コウジョウ ニ ツイテ

Search this article

Abstract

The efficacy of the administration of ezetimibe, a cholesterol transporter inhibitor, concomitantly with combination peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) therapy was retrospectively examined in patients with chronic hepatitis C (CHC). The subjects examined were 334 HCV genotype 1 high titer patients (44 receiving ezetimibe, 290 not receiving ezetimibe) treated with PEG-IFN/RBV in our hospital for whom conducting assessment of HCV RNA-negativity from the start of treatment to Week 12 in treatment (EVR: less than 50 IU/ml by Amplicore method) was performed. The EVR rate was 65.9% in the group receiving ezetimibe, which was significantly higher (p=0.002) compared to 45.2% in the group not receiving ezetimibe. In multivariate analysis, concomitant administration of ezetimibe was selected as a factor contributing to EVR (odds ratio: 2.993, p=0.004). The cumulative HCV RNA negativity rate was also significantly higher in the group receiving ezetimibe (p=0.0035). However, a tendency of higher EVR rate was observed with the group receiving ezetimibe than with the group not receiving ezetimibe regardless of the presence or absence of hepatic steatosis in pretreatment liver biopsy.<br> The results suggest the possibility that the concomitant administration of ezetimibe might be useful for improving the results of PEG-IFN/RBV treatment in CHC.<br>

Journal

  • Kanzo

    Kanzo 51 (11), 607-614, 2010

    The Japan Society of Hepatology

References(35)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top